The calibration curves in plasma were linear for erlotinib, gefitinib an imatinib over the concentration range of 5-3000; 5-3000 and 5-5000 ng/m respectively. The intra-and interday accuracy ranged from 90%-110% and th intra-and interday precision of the method was within 5%. The reporte method provided the necessary linearity, precision and accuracy determine three tyrosine kinase inhibitors in clinical research and f therapeutic drug monitoring.
. Accuracy and precision of the method.
Simultaneous quantification of erlotinib, gefitinib and imatinib in human plasma by liquid chromatography tandem mass spectrometry

Introduction
Imatinib (Gleevec®), erlotinib (Terceva®) and gefitinib (Iressa®) are drugs which compete with ATP for binding at the tyrosine kinase receptor. Erlotinib and gefitinib are selective inhibitors of the epidermal growth factor receptor (EGFR), which is often overactive in tumors cells. Erlotinib and gefitinib are common used for treatment of non-small cell lung cancer. Imatinib is an inhibitor of the platet-derived growth factor (PDGF)-receptor and is mainly used by chronic myelogenous leukemia and gastrointestinal stromal tumors. The PDGF (Fig. 1) is one of the growth factors that regulate cell growth and division. Interindividual differences in absorption and metabolism exist and pharmacokinetic interaction with other drugs are described. In case of suspicion of nonadherence, drug-drug interaction, excessive side effects and poor effectiveness, therapeutic drug monitoring (TDM) is useful.
Aim
Implementing and developing a method for the simultaneous quantification of imatinib, erlotinib and gefitinib by LC-MS/MS. A simultaneous method for the analysis of these tyrosine kinase inhibitors is more efficient, improves clinical usefulness and makes frequent assaying possible.
Method
Pre-treatment of the samples was achieved by using liquid-liquid extraction using D-8 imatinib as internal standard. Separation was performed on a Waters® Alliance 2795 LC-system using an XBridge® RP18 column. The mass spectrometer Micromass® was operating in the positive electro spray ionization mode. The analytes were detected by multiple reaction monitoring (MRM), monitoring the transition of the m/z precursor to the m/z of the product ion. 
Conclusion:
The developed method is sensitive and specific for the simultaneous quantification of erlotinib, gefitinib and imatinib in human plasma by LC-MS/MS. The data confirms that the developed method is robust and has a satisfying accuracy and precision for the quantification of imatinib, erlotinib and gefitinib. This method is suitable for therapeutic drug monitoring and for clinical research. Av.= average, Acc. = accuracy
Applicability of the assay in clinical practise
The laboratory of clinical pharmacology and pharmacy participates in European treatment outcome study (EUTOS) of chronic myelogen leukaemia initiated by Novartis. The aim of this study is providing availability of imatinib monitoring on an European level. For this study plasma samples were analyzed, the results of the laboratory of clin pharmacology and pharmacy (NL01) are described in figure 3 . In a study Picard et al is mentioned that the effectively doses for imatinib a pla threshold of 1000 ng/ml is considered. Routinely the method is mainly used for TDM of patients which treat w erlotinib. Based on the study of Hidalgo a plasma concentration of 500 u have been estimated to provide a level of EGFR inhibition associated wit relevant degree of antiproliferative activity. 
